Jasper Therapeutics shares surge 22.11% after-hours after reporting positive ETESIAN study data and resolving BEACON study issues.

Jasper Therapeutics surged 22.11% in after-hours trading following the release of positive preliminary data from its ETESIAN Phase 1b/2a study of briquilimab in asthma and the resolution of concerns from its BEACON study. The ETESIAN results showed significant reductions in airway hyperresponsiveness, eosinophilic inflammation, and serum tryptase after a single 180mg dose of briquilimab, supporting its potential as a novel asthma treatment. Additionally, Jasper concluded its BEACON study investigation, confirming no drug-product issues and attributing prior underperformance to patient selection errors. The favorable safety profile of briquilimab and the study’s proof-of-concept for mast cell depletion in asthma reinforced investor optimism about its therapeutic potential. The company’s upcoming conference call to discuss findings further amplified market reaction.